Eli Lilly is developing EloraTZP, a new triple-pathway treatment that is not retatrutide. 🔬 What Is EloraTZP? EloraTZP combines: - Eloralintide → amylin receptor agonist - Tirzepatide → GIP + GLP-1 agonist So the three pathways are: Amylin + GIP + GLP-1 Retatrutide is different: GIP + GLP-1 + glucagon 🧠 How Does It Work? The key addition is amylin, a hormone naturally released with insulin after eating that helps regulate fullness, appetite, and food intake. The idea is to combine that appetite/satiety pathway with the GIP + GLP-1 effects of tirzepatide to potentially produce greater weight-loss and metabolic effects. 📈 Where Is It Now? Eloralintide alone has progressed into Phase 3, while the EloraTZP combination recently completed a 48-week Phase 2b study. Lilly reported average weight loss of up to 23.3% with EloraTZP in the study, compared with 14.8% with tirzepatide 15 mg. Lilly plans to move EloraTZP into Phase 3.